Pfizer Corporation

Other

Pharmacia & Upjohn Company

Jeffrey Allen Pfefferkorn

Meihua Mike Tu

Angel Guzman-Perez

Kevin James Filipski

Mary Theresa Didiuk

Benjamin Dawson Stevens

Gary Erik Aspnes

Esther Cheng Yin Lee

John William Benbow

Richard Allen Nugent

Anthony Lai Ling

Jihong Lou

Meredith L Greene

Robert C Kelly

Patrick Robert Verhoest

Fan Yang

Benjamin C Stevens

Esther C Lee

Mark Allen Mitchell

Ke Chen

Lee Andrew Funk

William Paul Esler

Nancy Anne Wicnienski

Bo Zhang

Barry Craig Finzel

Matthew Todd Reding

Rebecca Merry Anderson

Albert Myung Kim

Roberto Arnaldo Calle

Richard Frederick Heier, Iii

Hua Gao

Rebecca J Gross

Arthur James Bergman

Neeta Balkrishan Amin

Esther Cheng Lee

A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.

Combinations for treatment of NAFLD/NASH and related diseases

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R, R, R, A, A, A, A, L, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Quinolinyl glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon. 

The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.

Benzofuranyl derivatives

The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R, R, R, and Rareas described herein.

(S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator

The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R, R, R, and Rare as described herein.

Substituted imidazoles useful for treating type II diabetes

The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. The variables R, R, Rand Rare as described herein.

Substituted pyrazinone amides useful for activation of glucokinase

Growing community of inventors

Acton, MA, United States of America

Jeffrey Allen Pfefferkorn